We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
Read MoreHide Full Article
QIAGEN N.V. (QGEN - Free Report) recently launched QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.
The latest development will strongly boost the QIAGEN Digital Insights (“QDI”) bioinformatics business of the Genomics / NGS product group.
News in Detail
QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources. It identifies and extracts causal relationships between genes, diseases, drugs and other biological entities with AI, generating more than 600 million more biomedical relationships than its complement, QIAGEN Biomedical KB-HD. This expansive knowledge base helps data scientists understand disease mechanisms, identify drug targets or biomarkers and explore strategies for repurposing existing drugs.
Image Source: Zacks Investment Research
While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains more than 25 times more relationships, allowing data scientists to generate new insights. Both knowledge bases can be used to provide both high-quality and high-quantity biomedical relationship data for data scientists and bioinformaticians to mine and validate.
The key features of QIAGEN Biomedical KB-AI also include structured results in an ontology for rapid querying, advanced analytics and quarterly updates to capture the most recent research and discoveries. By combining the strengths of AI and human curation approaches, QIAGEN Biomedical KB-AI signifies a major step forward in the company’s mission to empower biopharma customers with the most comprehensive and informative molecular knowledge bases.
Industry Prospects
Per a Research report, the global drug discovery market was valued at $55.46 billion in 2022 and is expected to witness a CAGR of 9.2% up to 2032.
Other Developments in the QDI Business
In January 2024, QIAGEN announced an enhanced CLC Genomics Workbench Premium with LightSpeed technology, which supports next-generation sequencing for somatic cancer secondary analysis. Having launched last year for germline applications, including whole genome sequencing, whole-exome sequencing and large panel sequencing data, the new capabilities enable small and large labs to significantly reduce turnaround time in oncology testing by removing key barriers in the analysis cost and speed.
Further, the company announced strategic plans to accelerate investments in this business over the next five years. The investments will support QDI’s profitable expansion into new geographic regions and market segments and deliver enhanced customer insights and new products. The investment will also extend QDI’s existing augmented molecular intelligence approach with additional AI and Natural Language Processing capabilities and also a new regulatory-compliant secondary analysis solution for rapid NGS analysis within clinical labs.
Price Performance
In the past six months, QGEN shares have dropped 2.1% against the industry’s 4.8% rise.
Cardinal Health’s stock has increased 51.8% in the past year. Earnings estimates for Cardinal Health have risen from $6.91 to $7.28 in fiscal 2024 and from $7.76 to $8.03 in fiscal 2025 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.7%.
Estimates for Stryker’s 2024 earnings per share have increased from $11.79 to $11.86 in the past 30 days. Shares of the company have moved 32% upward in the past year compared with the industry’s rise of 5.7%.
SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an average earnings surprise of 5.8%.
Estimates for DaVita’s 2024 earnings per share have moved from $8.46 to $8.97 in the past 30 days. Shares of the company have increased 45.6% in the past year compared with the industry’s 7.9% rise.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. In the last reported quarter, it delivered an average earnings surprise of 22.2%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
QIAGEN N.V. (QGEN - Free Report) recently launched QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.
The latest development will strongly boost the QIAGEN Digital Insights (“QDI”) bioinformatics business of the Genomics / NGS product group.
News in Detail
QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources. It identifies and extracts causal relationships between genes, diseases, drugs and other biological entities with AI, generating more than 600 million more biomedical relationships than its complement, QIAGEN Biomedical KB-HD. This expansive knowledge base helps data scientists understand disease mechanisms, identify drug targets or biomarkers and explore strategies for repurposing existing drugs.
Image Source: Zacks Investment Research
While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains more than 25 times more relationships, allowing data scientists to generate new insights. Both knowledge bases can be used to provide both high-quality and high-quantity biomedical relationship data for data scientists and bioinformaticians to mine and validate.
The key features of QIAGEN Biomedical KB-AI also include structured results in an ontology for rapid querying, advanced analytics and quarterly updates to capture the most recent research and discoveries. By combining the strengths of AI and human curation approaches, QIAGEN Biomedical KB-AI signifies a major step forward in the company’s mission to empower biopharma customers with the most comprehensive and informative molecular knowledge bases.
Industry Prospects
Per a Research report, the global drug discovery market was valued at $55.46 billion in 2022 and is expected to witness a CAGR of 9.2% up to 2032.
Other Developments in the QDI Business
In January 2024, QIAGEN announced an enhanced CLC Genomics Workbench Premium with LightSpeed technology, which supports next-generation sequencing for somatic cancer secondary analysis. Having launched last year for germline applications, including whole genome sequencing, whole-exome sequencing and large panel sequencing data, the new capabilities enable small and large labs to significantly reduce turnaround time in oncology testing by removing key barriers in the analysis cost and speed.
Further, the company announced strategic plans to accelerate investments in this business over the next five years. The investments will support QDI’s profitable expansion into new geographic regions and market segments and deliver enhanced customer insights and new products. The investment will also extend QDI’s existing augmented molecular intelligence approach with additional AI and Natural Language Processing capabilities and also a new regulatory-compliant secondary analysis solution for rapid NGS analysis within clinical labs.
Price Performance
In the past six months, QGEN shares have dropped 2.1% against the industry’s 4.8% rise.
Zacks Rank and Key Picks
QIAGEN currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Cardinal Health (CAH - Free Report) , Stryker (SYK - Free Report) and DaVita (DVA - Free Report) . While Stryker carries a Zacks Rank #2 (Buy), Cardinal Health and DaVita each sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health’s stock has increased 51.8% in the past year. Earnings estimates for Cardinal Health have risen from $6.91 to $7.28 in fiscal 2024 and from $7.76 to $8.03 in fiscal 2025 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.7%.
Estimates for Stryker’s 2024 earnings per share have increased from $11.79 to $11.86 in the past 30 days. Shares of the company have moved 32% upward in the past year compared with the industry’s rise of 5.7%.
SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an average earnings surprise of 5.8%.
Estimates for DaVita’s 2024 earnings per share have moved from $8.46 to $8.97 in the past 30 days. Shares of the company have increased 45.6% in the past year compared with the industry’s 7.9% rise.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.6%. In the last reported quarter, it delivered an average earnings surprise of 22.2%.